A Phase 1, Single-center, Double-blind, Randomized, Cross-over, Pharmacokinetics, Safety and Tolerability Study of SB204 8% (NVN1000 Gel) and Vehicle Gel

Trial Profile

A Phase 1, Single-center, Double-blind, Randomized, Cross-over, Pharmacokinetics, Safety and Tolerability Study of SB204 8% (NVN1000 Gel) and Vehicle Gel

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Acne vulgaris
  • Focus Pharmacokinetics
  • Sponsors Novan Inc
  • Most Recent Events

    • 27 Apr 2017 Results from this trial will be presented at the 76th Annual Meeting of the Society for Investigative Dermatology 2017, as per a Novan therapeutics media release.
    • 10 Jun 2015 Results will be presented at the 23rd World Congress of Dermatology (WCD), as per Novan therapeutics media release.
    • 02 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top